Study on the clinical mechanism of Tongxieanchangfang in the treatment of diarrheal irritable bowel syndrome based on single-cell sequencing technology
- Conditions
- Irritable Bowel Syndrome
- Registration Number
- ITMCTR2100004327
- Lead Sponsor
- Dongfang Hospital Beijing University of Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
1. Patients with IBS-D diagnosed by western medicine;
2. Patients with IBS-SSS score > 75;
3. Patients with liver depression and spleen deficiency syndrome according to TCM syndrome differentiation;
4. Patients aged 18-65 years;
5. Subjects who signed informed consent.
1. Patients with intestinal organic lesions (colonoscopy or colonoscopy report within 3 months);
2. Patients with contraindications of colonoscopy;
3. Patients with severe pathological changes of liver, brain, kidney and other major organs, and patients with mental disorders;
4. Patients with systemic diseases affecting gastrointestinal motility (such as hyperthyroidism, diabetes, chronic renal insufficiency, etc.);
5. Pregnant women and lactating women;
6. The patients who used other drugs to treat irritable bowel syndrome in the first week were screened;
7. Patients with allergic constitution, and those who are allergic to the known ingredients and any excipients of the drug in this study;
8. Patients with suspected or true history of alcohol or drug abuse;
9. Patients who participated in other clinical trials within three months.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Fecal traits;Abdominal pain intensity;
- Secondary Outcome Measures
Name Time Method IBS Symptom Severity Scale;Quality of life score;Effectiveness of TCM Syndrome;Single symptom analysis;Two-class result measurement index;